BioNTech SE BNTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.03% | 10.05% | 11.45% | 6.95% | 7.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.03% | 10.05% | 11.45% | 6.95% | 7.44% |
| Cost of Revenue | 14.43% | 14.34% | 19.84% | 17.34% | 26.88% |
| Gross Profit | -4.95% | 8.94% | 9.41% | 5.02% | 3.43% |
| SG&A Expenses | 41.53% | 20.39% | 9.58% | -9.56% | -11.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 234.53% | 45.02% | 39.21% | 316.83% | 346.40% |
| Total Operating Expenses | 32.28% | 12.97% | 9.02% | 17.86% | 18.93% |
| Operating Income | -153.40% | -19.14% | -3.81% | -93.57% | -94.56% |
| Income Before Tax | -341.47% | -61.52% | -58.69% | -69.83% | -61.72% |
| Income Tax Expenses | 237.37% | 430.70% | 796.32% | -64.47% | -117.38% |
| Earnings from Continuing Operations | -414.65% | -78.40% | -76.39% | -26.46% | 29.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -414.65% | -78.40% | -76.39% | -26.46% | 29.76% |
| EBIT | -153.40% | -19.14% | -3.81% | -93.57% | -94.56% |
| EBITDA | -165.46% | -13.97% | -3.14% | -84.48% | -118.59% |
| EPS Basic | -393.80% | -73.39% | -75.22% | -26.18% | 29.71% |
| Normalized Basic EPS | -402.22% | -63.86% | -79.61% | -117.96% | -70.28% |
| EPS Diluted | -389.56% | -72.69% | -74.42% | -24.80% | 29.88% |
| Normalized Diluted EPS | -398.26% | -63.29% | -78.83% | -112.02% | -65.19% |
| Average Basic Shares Outstanding | 2.69% | 1.61% | 0.24% | -0.09% | 0.36% |
| Average Diluted Shares Outstanding | 2.38% | 1.29% | -0.07% | -0.53% | 0.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |